ArticleBMC biotechnology2025
Tumor microenvironment-activated ROS enhancers for effective inhibition of osteosarcoma.
Article in BMC biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Recent Advances in Smart Stimulus-Responsive Hydrogels for Precision Drug Delivery in Tumours.Gels (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Reactive oxygen species (ROS) in the tumor microenvironment (TME) are key factors involved in inhibiting tumor cell proliferation. This study developed a hollow mesoporous silica-Prussian blue (HMSNs-PB) nanozyme delivery platform loaded with metformin (HPB@MET), which enhances ROS levels within tumor cells through peroxidase-like (POD) activity. Moreover, in the acidic microenvironment of tumors, HPB@MET disintegrates, and the released MET causes mitochondrial dysfunction and increased electron leakage, ultimately promoting the abnormal accumulation of ROS in the TME. In vitro experiments demonstrate that HPB@MET achieves peak cellular uptake at 72 h and significantly inhibits tumor cell proliferation through its exceptional ROS-generating capacity. In the K7M2 osteosarcoma model (initial tumor volume 80 mm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.